MAIA Biotechnology shares are trading lower. The company reported new clinical data from its Phase 2 THIO-101 clinical trial evaluating THIO sequenced with the immune checkpoint inhibitor cemiplimab in patients with advanced non-small cell lung cancer who failed 2 or more standard-of-care therapy regimens.
$MAIA
Biotechnology: Pharmaceutical Preparations
Health Care
MAIA Biotechnology shares are trading lower. The company reported new clinical data from its Phase 2 THIO-101 clinical trial evaluating THIO sequenced with the immune checkpoint inhibitor cemiplimab in patients with advanced non-small cell lung cancer who failed 2 or more standard-of-care therapy regimens.